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An analysis of more than 500 liver transplants has 
demonstrated that HLA compatibility is associated with 
diminished allograft survival. Liver transplants with 
zero mismatches for class I and/or class II HLA antigens 
have shown significantly lower actuarial survival rates 
than transplants with one or more mismatches for these 
loci. In a group of 119 failed liver allografts from pa-
tients undergoing retransplantation, a higher incidence 
of failure due to rejection correlated with a lower degree 
of HLA compatibility especially for HLA-DR. In con-
trast, the incidence of liver transplant failures due to 
primary nonfunction was relatively higher with HLA-
DR compatible transplants. Considering the role of HLA 
as a restriction element in cellular interactions during 
the immune response. these findings suggest that HLA 
compatibility may have a dualistic effect on liver trans-
plant outcome. On one hand, HLA compatibility reduced 
transplant rejection-and on the other hand, it may 
enhance other immunological mechanisms leading to al-
lograft dysfunction, particularly in patients at risk of 
developing recurrent autoimmune diseases or infection. 
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HLA compatibility has been widely recognized to improve 
the outcome of kidney (1-3) and, probably, heart transplants 
(4), but no beneficial effect has been reported for liver trans-
plants (5, 6). Additionally, humoral sensitization to HLA an-
tigens prior to transplantation and a positive donor-specific 
crossmatch does not seem to influence liver allograft survival 
(7-9). In combined liver-kidney transplants, we have demon-
strated that removal of circulating donor-specific antibodies by 
the liver transplant is without adverse effect on the graft itself 
and, that subsequent kidney transplants show good function 
and no hyperacute rejection (10, 11). In certain instances, the 
liver allograft may undergo antibody-mediated hyperacute re-
jection (12). Presensitization and positive crossmatches have 
been interpreted by some investigators to be associated with 
an increased incidence of vanishing bile duct syndrome in liver 
transplant recipients (13). This syndrome may occur more 
often in liver transplants from class I HLA-incompatible do-
nors with a partial or complete match for class II DR antigens 
(14). HLA-specific alloreactive T cells have recently been dem-
onstrated in lymphocyte cultures grown from hepatic allografts, 
providing evidence that HLA antigens are involved in cellular 
immune mechanisms leading to rejection of liver allografts (15, 
16). 
In view of the role of HLA in transplant immunity, we have 
recently examined the question of HLA compatibility and liver 
transplant survival. Our analysis of more than 500 liver allo-
grafts has confirmed previous findings that HLA compatibility 
does not improve overall survival of liver allografts. Here we 
present data that actually suggest that compatibility for both 
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class I and class II HLA antigens is associated with a significant 
decrease in liver transplant survival. These surprising findings 
can be explained by considering a dualistic role of HLA, 
whereby, on the one hand, HLA operates as a system of 
transplantation antigens important in allograft rejection and, 
on the other hand, it functions as restriction element (self-
recognition) important in cellular processes leading to cell-
mediated immunological damage to the liver transplant. 
MATERIALS AND METHODS 
Between March 1980 and December 1986, 1053 orthotopic liver 
transplants were performed and 821 patients received first allografts, 
while second and third transplants were done in 232 patients. Of these, 
527 adults were given 654 grafts and 294 children were given 399 grafts. 
All patients have been fonowed through July 1, 1987 and received 
cyclosporine and steroids as immunosuppressive drugs. As of December 
1984 OKT3 monoclonal antibody therapy has been added to treat acute 
rejection episodes (17). 
HLA typing was performed using the Amos modified (class I HLA 
antigens) and two-color fluorochromasia (class II HLA antigens) tech-
niques. The tissue typing results were generally obtained shortly fol-
lowing transplantation and therefore played no role in recipient selec· 
tion. Data on HLA-A, B phenotypes were available for 574 donor-
recipient pairs, 458 of which had primary transplants. In this group, 
78% were adult recipients (18 yelU'll or older) and 22% were pediatric 
patients. For 507 donor· recipient combinations, we had data for HLA-
DR antigens, 405 of whom were primary transplants. HLA-DQ phen-
otyping was done on insufficient numbers of patients and donors; 
therefore matching for DQ was not evaluated. 
This analysis also included liver transplants performed at Baylor 
Medical Center in Dallas. Donor and recipient HLA A.B phenotypes 
were obtained for 64 cases (11.1% of the total group) and 55 (10.8%) 
of the donor· recipient pairs were typed for HLA-DR. 
The age of patients in this study group ranged from 0.6 to 67.9 years 
(mean 33.3±17.8 yelU'll). The most common primary indications for 
liver replacement in these patients included cirrhosis (35.8%), primary 
biliary cirrhosis (21.0%), biliary atresia (10.9%), sclerosing cholangitis 
(9.8%), inborn errors of metabolism (9.2%), and primary liver tumors 
(4.4%). 
Actuarial survival of liver allografts with various degrees of HLA 
compatibility was calculated by the life-tsble method. Criteria for 
transplant failures included patient death and allograft removal reo 
gardless of graft function. Statistical analysis of transplant survival 
rates was done by the Breslow (generalized Wilcoxon) and Mantel·Cox 
(generalized Savage) tests using the lL program of the BMDP software 
package (BMDP Statistical Software. Inc., Los Angeles, CAl (18). The 
Breslow test is weighted toward earlier events and the Mantel-Cox test 
emphasizes differences later during the posttransplant period. 
Statistical analysis of differences between the match· groups was 
done with the 4F program of the BMDP software package and Pearson 
chi-square statistics. 
RESULTS 
The analysis of the effect of HLA compatibility on liver 
transplant survival was based on the number of donor antigens 
mismatched at the HLA-A, HLA-B. and HLA-DR loci. The 
results considered both primary grafts and retransplants. Over-
all actuarial survival for the 574 liver allografts included in this 
analysis was 59.2% for the one-year and 55.2% for the two-year 
period. Figure 1 shows the survival rates of liver allografts with 
zero, one, and two HLA-A mismatches. Lower survival rates 
were observed for transplants with zero mismatches as com-
pared with transplants with one or two HLA-A mismatches. 
The differences between the zero versus one and two mis-
matches were statistically significant as determined by Breslow 
analysis (early events, P=0.057) and Mantel-Cox (late events, 
P=O.029). The one-year survival rates were 41.1 % of the zero 
(n=42) and 60.6% of the one- and two- (n=532) HLA-A antigen 
mismatch groups. After two years, the survival rates were 36.5% 
and 56.7%, respectively. Survival rates of one and two HLA-A 
mismatched liver transplants were approximately the same. 
The numbers of patients in the group of zero mismatches at 
HLA-B was too small (n=12) to permit a meaningful statistical 
analysis of the effect of HLA -B compatibility. 
The effect of compatibility for HLA-DR on liver transplant 
outcome is illustrated in Figure 2. The group of zero HLA-DR 
mismatches showed longer survival rates than transplants with 
one and two HLA-DR mismatches (Breslow: P=0.054; Mantel-
Cox: P=O.087). Transplant survivals after one year were 51.9% 
for zero HLA-DR mismatches (n=52) and 60.3% for one or two 
HLA-DR mismatches (n=455)_ After two years, the survival 
rates were 45.0% and 56.9%, respectively. 
In 507 transplants with complete typing information for all 
HLA-A, B and DR loci. we identified 91 patients for whom 
there was a zero mismatch for at least one of these loci. Highly 
significantly lower survival rates were observed with this group 
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FIGURE 1. Actuarial survival of 574 liver transplants with different 
degrees of HLA-A incompatibility. The differences between the zero 
versus one and two mismatches for HLA-A were statistically significant 
as determined by Breslow analysis (early events): P=0.057; and by 
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FIGURE 2. Actuarial survival of 507 liver transplants with different 
degrees of HLA-DR incompatibility. The group of zero HLA-DR mis-
matches showed significantly lo_r survival rates than transplants 
with one and two HLA-DR mismatches (Breslow: P-O.054; Mantel-
Cox: P=0.087). 
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as compared with the remaining group of 416 patients receiving 
transplants without zero mismatches at any of the HLA-A, B 
or DR loci (Breslow: P=0.OO8; Mantel-Cox: P=O.OO8) (Fig. 3). 
Transplant survivals of the two groups were after one year 
47.7% and 61.9%, and after two years 44.1% and 58.3%, re-
spectively. 
This study also considered a group of patients, who were 
retransplanted after their initial allograft had failed. A total of 
119 failures were classified into three diagnostic categories 
based on clinical and pathological assessment as previously 
described (19). A diagnosis of rejection was made for 53 failed 
allografts (44.5%), whereas in 31 cases (26.1%) the cause of 
failure was primary nonfunction. A third group of 35 failures 
(29.4%) included vascular thrombosis, "technical" complica-
tions, and 4 cases of infection. 
Table 1 shows the incidence of different causes of liver 
transplant failure in the various HLA match categories. Com-
plete HLA-DR typing data were available for 108 failed allo-
grafts. In the group of 13 zero mismatches for HLA-DR, pri-
mary nonfunction was the most frequently observed cause of 
transplant failure (61.5%). A diagnosis of rejection was made 
for only 2 zero-HLA-DR mismatches (15.4%). An increasing 
degree of HLA -DR incompatibility was associated with a higher 
incidence of rejection but a lower frequency of graft failures 
caused by primary nonfunction. The differences in HLA-DR 
effects on rejection and primary nonfunction were statistically 
significant (P=0.007), whereas no HLA-DR influence was 
noted on liver allograft failures from other causes. 
The data in Table 1 also showed a similar trend toward an 
association of HLA-A and HLA-B incompatibility with an 
increased incidence of rejection, but the effect in comparison 
with other groups was not statistically significant (P<O.10). 
The lack of statistical significance might be due to the relatively 
low numbers of observations in each group. It was also noted 
that the incidence of transplant failures from other causes (i.e., 
vascular thrombosis, technical complications, and infections) 
was higher among allografts from donors with zero mismatches 
for HLA-A and HLA-B. However, the differences were statis-
tically insignificant (1)>0.10). We also observed that a combi-
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FIGURE 3. In 507 transplants with complete typing information for 
all HLA·A. B. and DR loci. 91 patients were identified for whom there 
wu a zero mismatch for at leaat one of these loci. Highly significant 
lower lurvival ratea were observed with thil group 81 compared with 
the remaining group of 416 patients receiving tranaplants without zero 
miamatchea at any of the HLA·A. B. or DR loci (Breslow: ~KMMU; 
Mantel-Cox: P-O.OO8). 
TABLE 1. Frequencies of causes of failures of HLA-matched and· 
mismatched liver transplanta in patienta requiring retranapiantation 
Frequency of cause of failures 
No.HLA No. 
miamatches transplants Rejection Primary Other"' nonfunction 
OHLA·DR 13 15.4% 61.5% 23.1% 
1 HLA·DR 31 35.5% 29.0% 35.5% 
2 HLA·DR 64 50.0%b 18.8%b 31.3% 
o HLA·A 12 33.3% 25.0% 41.7% 
1 HLA-A 46 43.5% 28.3% 28.3% 
2HLA·A 61 47.5% 24.6% 27.9% 
OHLA·B 6 16.7% 16.7% 66.7% 
1 HLA·B 22 36.4% 36.4% 27.3% 
2 HLA·B 91 48.4% 24.2% 27.5% 
OHLA·Aor 17 29.4% 23.5% 47.1% 
OHLA·B 
NoO HLA· 102 47.1%' 26.5% 26.5%' 
A and no 
OHLA·B 
• Other causes of failure include vaacular thrombosis, technical com· 
plications. and 4 cases of infection. 
b The differences in HLA-DR effects on rejection and primary non· 
function were statistically significant (P = 0.007). 
'The combination of zero mismatches for either· HLA-A or HLA-B 
W81 aasociated with a lower incidence of rejection, but a higher free 
quency of other cauaea of graft failures 81 compared with transplanta 
with one or more HLA-A and HLA-B mismatches. The differences 
between these groups were of borderline statistical significance (P = 
0.082). 
nation of zero mismatches for either HLA·A or HLA·B was 
associated with a lower incidence of rejection, but a higher 
frequency of other causes of graft failures as compared with 
transplants with one or more HLA-A and HLA-B mismatches. 
The differences between these groups were of borderline statis-
tical significance (P=0.082). 
DISCUSSION 
These data suggest that HLA compatibility is associated with 
a decreased survival of liver transplants. The effect is evident 
for both class I antigens of HLA-A and class II antigens of the 
HLA-DR locus. The number of cases available was not suffi· 
cient to evaluate the influence of the highly polymorphic HLA· 
B locus. The present findings are in contrast to the widely 
reported beneficial effect of HLA compatibility on kidney 
transplant outcome (1-3). 
Our inability to demonstrate a favorable effect of matching 
for HLA on liver transplant survival does not necessarily 
conflict with the concept that HLA influences transplant rejec-
tion of liver allografts. This is apparent from our observations 
that the frequency of liver transplant failures caused by rejec-
tion correlated with the degree of HLA mismatching, especially 
for HLA-DR. Additional evidence for the role of HLA as 
transplantation antigens in liver allograft immunity has been 
obtained with studies of transplant biopsy-grown lymphocytes 
(I5. 16). Such graft infUtrating cells may exhibit alloreactivity 
specific for class I and/or class II HLA antigens of the donor. 
The inflltration by class II-specific cells is associated with 
increased serum levels of gamma glutamyl transpeptidase and 
alkaline phosphatase (20). During rejection. the biliary epithe· 
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lium shows strong expression of class II HLA antigens and 
constitutes a prefened target for graft-infiltrating lymphocytes 
(21). Class I-specific cells seem primarily involved in the early 
events of allograft rejection when the vascular endothelium 
expresses mostly class I HLA antigens (22). 
Besides transplant rejection induced by HLA incompatibil-
ity, other immunological m~chanisms might induce liver trans-
plant failure. These mechanisms could be specific for a variety 
of antigens including viruses, autoantigens, and tissue-specific 
components. An important consideration is the immunological 
etiology and many end-stage liver diseases, including primary 
biliary cirrhosis (23), sclerosing cholangitis (24), autoimmune 
chronic active hepatitis, and viral hepatitis (25). Following 
transplantation, a persistence of disease-associated immuno-
logical mechanisms may lead to a recunence of liver failure. 
An important consideration is the influence of HLA-espe-
cially in view of our fmdings that HLA compatibility is asso-
ciated with decreased liver transplant survival and a higher 
incidence of non-rejection-related transplant failures. 
One of the most distinctive features of HLA is its role in 
cellular interactions during the immune response. This phe-
nomenon is refened to as major histocompatibility complex 
restriction and has been observed in several animal species (26, 
27). Many cellular interactions are HLA restricted-that is, 
they are efficient only if the cells involved express shared HLA 
antigens. This MHC restriction (or self-recognition) has been 
demonstrated at several levels during the immune response, 
especially in interactions between antigen-presenting cells and 
T lymphocytes (28) and in cytotoxic T cell-induced lysis of 
virus-infected and other antigen-expressing target cells (29). 
HLA restriction has been demonstrated for cellular immunity 
to clinically relevant viral antigens, such as cytomegalovirus 
(30-32), Epstein-Barr virus (33,34) and herpes simplex (35). 
During infection, cytotoxic lymphocyte-mediated damage 
would probably be more efficient if infected target cells in the 
allograft expressed compatible HLA antigens. 
The phenomenon of HLA restriction has not been exten-
sively studied in autoimmune liver diseases, because the anti-
gens involved are largely undefined. However, HLA has been 
indirectly implemented through its association with several 
liver diseases (36, 37). Associations have been reported for 
chronic active hepatitis with ORa (38), sclerosing cholangitis 
with B8 (39), and alcoholic cirrhosis with DR2 (40). Thus far, 
published reports show no association of HLA-A or -B antigens 
with primary biliary cirrhosis (36, 41, 42), although there 
appears to be a genetic predisposition from the substantial 
number of intrafamilial cases of primary biliary cirrhosis (43). 
Relatives of patients have a higher-than-expected frequency of 
other autoimmune diseases (44). Our analysis of 74 female 
primary biliary cirrhosis patients has demonstrated an in-
creased frequency of HLA-DR7 (manuscript in preparation). 
The HLA associations with these diseases can be explained 
with the presence of HLA-linked immune response genes that 
influence immunological mechanisms relevant to disease proc-
esses (27). The products of these genes could operate through 
MHC restriction in various cellular interactions during the 
immune response. These processes would not only affect the 
original liver, but also contribute to recunent disease of the 
transplanted liver, especially from an HLA compatible donor. 
Disease recunence in liver transplant patients has been 
documented in patients with chronic active hepatitis B (45, 
46), hepatic malignancies (47,48) and Budd-Chiari syndrome 
(49-51). However, the diagnosis of recurrent disease is much 
more difficult in transplant patients with primary biliary cir-
rhosis (50, 52), non-A non-B hepatitis, and sclerosing cholan-
gitis (50). The difficulties arise from apparent pathophysiologic 
similarities between primary biliary sclerosis and chronic rejec-
tion; the lack of a specific marker for non-A, non-B hepatitis; 
and the problem with postoperative biliary strictures for scle-
rosing cholangitis. Functional studies of lymphocytes propa-
gated from liver allografts may enable a better differentiation 
between transplant rejection and other immunological mecha-
nisms leading to hepatic dysfunction. 
It has recently been reported, that pancreas transplants from 
HLA-identical donors show a high incidence of isletitis and 
recunent diabetes (53). The occunence of isletitis, associated 
with a T cell and macrophage inflltrate, was more pronounced 
in HLA-identical grafts, suggesting that this isletitis might be 
initiated by the recognition of identical MHC antigens shared 
between donor and recipient. It was suggested that the selective 
destruction of beta cells in HLA-identical grafts represents an 
anamnestic cytotoxic T lymphocyte-mediated autoimmune re-
sponse (54), whereas isletitis in nonidentical grafts is caused 
by rejection due to class I and class II HLA antigen disparity. 
Recurrent disease may also be a complication in renal trans-
plantation. This particularly applies to patients with focal 
segmental glomerulosclerosis (55, 56), IgA nephropathy (57), 
and membranous glomerulopathy (55, 58) who receive kidney 
transplants from HLA compatible donors. Interestingly, several 
of these renal diseases have an immunological basis and show 
HLA associations (36). For instance, IgA nephropathy possibly 
associates with DR4 (59) and membranous glomerulopathy 
with ORa and B18 (60). No studies have been reported thus 
far on the HLA association with focal segmented glomerulo-
sclerosis. The HLA associations with certain renal diseases and 
the increased disease recunence in HLA-compatible kidney 
transplants suggests that HLA is involved in these two related 
phenomena. The most likely mechanism is that HLA functions 
as a restriction element during immunological processes in-
volved in the pathogenesis of these diseases. Nevertheless, 
disease recurrence is relatively uncommon in kidney transplan-
tation. Thus the potentially adverse effect of HLA compatibil-
ity in promoting disease recurrence is negated by the large 
number of cases wherein HLA compatibility enhances renal 
transplant survival through decreasing allograft rejection. On 
the other hand, disease recurrence is more common in liver 
transplantation, and the possibility that HLA compatibility 
may increase disease recunence may explain the lower survival 
rates of HLA-compatible liver allografts. 
Another explanation for the association of HLA compatibil-
ity with decreased liver transplant survival is based on the 
concept that MHC restriction may also operate in transplant 
immunity. This has been demonstrated using in vitro assays 
(61,62) and in several allograft models in mice, wherein trans-
plant rejection across minor histocompatibility barriers was 
shown to be restricted by H-2 (63). In the human situation, 
HLA restriction of transplant immunity to the male-specific 
H -Y antigen has been observed in bone marrow transplantation 
(64) and following rejection of a kidney transplant from an 
HLA-identical male sibling donor (65). It has recently been 
reported that liver transplants with a complete mismatch for 
class I antigens, together with a partial or complete match for 
class II HLA antigens, experience a high incidence of vanishing 
bile duct syndrome, a manifestation of chronic rejection involv-
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ing biliary epithelium (14). An hypothesis has been forwarded 
that cytotoxic T cells sensitized to class I antigens would 
recognize bile duct epithelium in the context of class II com-
patibility between target and effector cells (14). Thus it is 
possible that MHC-restricted transplant rejection mechanisms 
may influence liver transplant outcome. 
The data presented in Figure 3 suggest that compatibility for 
only one of the HLA loci (Le., HLA-A, -B, or -DR) is already 
sufficient to cause a significant decrease in liver allograft sur-
vival. This could mean that compatibility for a single HLA 
locus may significantly enhance MHC-restricted immunologi-
cal mechanisms of liver allograft injury associated with viral 
infection and recurrent autoimmune disease. 
In summary, our present findings suggest that HLA compat-
ibility has a dualistic effect on liver transplant outcome: on the 
one hand it may reduce the rejection process, whereas, on the 
other hand, it may enhance other immunological mechanisms 
leading to allograft dysfunction. The practical implication of 
this concept is that the degree of HLA compatibility of liver 
allografts might be considered in the selection and management 
of transplant recipients, especially those at risk of developing 
recurrent disease or immunologically mediated complications 
other than rejection. 
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